157 related articles for article (PubMed ID: 32609585)
21. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
White EC; Goldman K; Aleshin A; Lien WW; Rao AR
Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
[TBL] [Abstract][Full Text] [Related]
22. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
El-Hadaad HA; Wahba HA; Roshdy S
J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
[TBL] [Abstract][Full Text] [Related]
23. [Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].
Pang XL; Liu S; Liu YP; Chen HY; He F; Zheng J; Wan XB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):977-983. PubMed ID: 34823298
[No Abstract] [Full Text] [Related]
24. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network.
DeFoe SG; Beriwal S; Jones H; Rakfal S; Heron DE; Kabolizadeh P; Smith RP; Lalonde R
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):424-31. PubMed ID: 22075444
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
26. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
27. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
28. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
[TBL] [Abstract][Full Text] [Related]
29. Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
Elson JK; Kachnic LA; Kharofa JR
Cancer; 2018 Nov; 124(22):4383-4392. PubMed ID: 30329160
[TBL] [Abstract][Full Text] [Related]
30. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Thind G; Johal B; Follwell M; Kennecke HF
Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
[TBL] [Abstract][Full Text] [Related]
31. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.
Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E
Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335
[TBL] [Abstract][Full Text] [Related]
32. Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients.
De Bari B; Lestrade L; Franzetti-Pellanda A; Jumeau R; Biggiogero M; Kountouri M; Matzinger O; Miralbell R; Bourhis J; Ozsahin M; Zilli T
J Cancer Res Clin Oncol; 2018 Apr; 144(4):781-789. PubMed ID: 29441419
[TBL] [Abstract][Full Text] [Related]
33. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
[TBL] [Abstract][Full Text] [Related]
34. Current treatment for localized anal carcinoma.
Das P; Crane CH; Ajani JA
Curr Opin Oncol; 2007 Jul; 19(4):396-400. PubMed ID: 17545807
[TBL] [Abstract][Full Text] [Related]
35. Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer.
Joseph K; Vos LJ; Warkentin H; Paulson K; Polkosnik LA; Usmani N; Tankel K; Severin D; Nijjar T; Schiller D; Wong C; Ghosh S; Mulder K; Field C
Radiother Oncol; 2016 Aug; 120(2):228-33. PubMed ID: 27406441
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization.
Kronborg C; Serup-Hansen E; Lefevre A; Wilken EE; Petersen JB; Hansen J; Schouboe A; Nyvang L; Spindler KG
Radiother Oncol; 2018 Aug; 128(2):375-379. PubMed ID: 29929860
[TBL] [Abstract][Full Text] [Related]
37. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
38. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
39. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
[TBL] [Abstract][Full Text] [Related]
40. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Hara W; Hsu A; Kunz PA; Ford J; Fisher GA; Welton ML; Shelton A; Kapp DS; Koong AC; Goodman KA; Chang DT
Cancer; 2011 Aug; 117(15):3342-51. PubMed ID: 21287530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
